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A B ST R AC T  
 
Aim: To determine our results by examining patient's files who we followed up by myelodysplastic 
syndrome (MDS) diagnosis between 2005 and 2009 as retrospectively and to compare the accordance 
of our results with literature. 
Methods: We examined 55 patient's files who got MDS diagnosis in 4 year-term. Complete blood 
count, biochemical analysis, peripheral spread, bone marrow aspiration, bone marrow biopsy 
examinations, cytogenetic and fluorescence in situ hybridization (FISH) analyses were made for all 
cases. 
Results: Our patient's age average was 69 and when classified according to WHO criterion at the 
diagnosis time, % 13 (23,6) of cases got diagnosed with RA-RARS, % 29 (52,7) with RCMD-RS, 
%5 (9,1) with RAEB-1, % 4 (7.3) with RAEB-2, % 3 (5.5) with MDS 5q and % 1 (1.8) with secondary 
MDS. % 52 of the patients had normal cytogenetic structure. No relation was determined between 
patients’ diagnosis and international prognostic scoring system (IPSS) scores. During the 4 year-term, 
our 13 patients died. 6 of these cases died by reason of transforming to acute myeloid leukemia 
(AML), and 7 patients died because of infection. Mean survival time of cases that died was 6 (1-7) 
months as of the diagnosis date. Whereas 8 cases were over 70 ages, 5 of our cases were under 70 
ages. 
Conclusion: MDS is a disease that ranges between anemia and AML and requires cytogenetic trials 
for diagnosis along bone marrow aspiration and biopsy for the purpose of determining the treatment 
regimen and prognosis. Determining the IPSS scores of patients by obtained outcomes is required. 
Risk of transforming to acute leukemia and susceptibility to infection are important in terms of 
mortality. Overage of patient population restricts the treatment regimens. Age must be an important 
factor for prognosis and treatment choice.  
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Introduction 
Myelodysplastic syndrome (MDS) is a disease 
which is characterized with cytopenia in one or 
more lines because of abnormal cellular 
proliferation in bone marrow and cellular 
proliferation’s being ineffective in peripheral 
blood that is seen in bone marrow. 
Additionally, it is a multipotent bone marrow 
disease that can develop primarily or 
secondarily [1], and the definitions about the 
disease have existed for almost 70 years 
although its MDS classification is new. In 
1938, Rhoades and Barker defined refractory 
anemia in 60 patients without any connection 
with another situation. Hamilton Peterson later 
defined the refractory anemia cases which 
occur before the development of acute myeloid 
leukemia as preleukemic anemia in order to 
define this situation [2]. Block et al. [2] used 
the term of ‘preleukemia’ to describe the 
patients, who had one or more refractory 
cytopenia that also included the potential of 
leukemic transformation in its natural course, 
in 1953. For the first time in 1976, a French-
American-British (FAB) group defined the 
diagnosis criteria for the pre-leukemic 
syndromes with refractory anemia, whose blast 
percentage was high, and chronic 
myelomonocytic leukemia, and this 
classification was revised in the year of 1982 
[3]. As well as the morphological 3 
classification, a separation can be made as 
primary or secondary MDS regarding whether 
it was exposed to chemotherapy, radiotherapy 
or toxic substances. 
The classification in the FAB system is based 
on the number of myeloblasts in bone marrow. 
The FAB system is successful to a certain 
extent in the prediction of the disease’s 
transformation to leukemia. Not taking into 
consideration such critical prognostic factors 
as the    cytogenetic    changes   and   previous  
 
treatment history for malign diseases, FAB 
classification’s capability to estimate the 
prognosis is limited. MDS in WHO 
classification; Refractory anemia (RA), 
Refractory anemia with ring sideroblast 
(RARS), Refractory cytopenia (RCMD, 
RCMD-RS) with increased dysplasia in 
multiple sequences without ring sideroblasts or 
ring sideroblasts (RAEB-1, RAEB-2), MDS 
and 5q syndrome divided into subgroups. 
Idiopathic MDS is an old age disease. Its 
average age to occur is around 68. There is a 
mild male gender dominance in the disease. 
The incidence in the general population is 35-
100/million people. It reaches 120-500/million 
people in the elderly. It is rare in children, but 
monocytic leukemia can be observed. 
Treatment-dependent MDS is not dependent 
on age, and the recurrence rate for the patients 
who took intense combined treatment models 
for cancer treatment is 15% [4]. 
In MDS, the course of the disease depends on 
the severity of the cytopenias and the number 
of blasts. In RA and RARS, which are included 
in the low-risk MDS group, the cytopenia 
becomes more severe in a long chronic 
process. As the result, the complications, 
belonging to cytopenia or treatment 
(transfusion hemochromatosis), occur. The 
transformation of these cases to acute myeloid 
leukemia (AML) is fewer, and the average of 
survival is longer [5]. 
The most important factors that affect the 
prognosis are age, the percentage of 
myeloblast in the bone marrow, the number of 
the cell lines, in which cytopenia is seen, and 
cytogenetic disorders. In an international 
study, made on prognosis in myelodysplasia, a 
prognostic scoring system (International 
prognostic scoring system - IPSS) was crated 
[6]. 
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MDS must be planned according to the 
subgroup, in which the patient’s treatment is 
found, and the prognostic score. Along with 
increasing the survival time which is the actual 
treatment purpose, the treatment goals must 
include delaying the transformation of 
leukemia, increasing the response rate, 
decreasing the transfusion need, decreasing 
infections and control, and increasing life 
quality with hematological correction. In the 
patients, who are younger and have a suitable 
health condition, the only known treatment 
method for long-term survival is allogeneic 
bone marrow transplantation. The treatments, 
except for this, must be supportive cares. In the 
present study, we aimed to retrospectively 
review the files of patients with MDS between 
2005 and 2009 and compare our results with 
the literature. 
 
Methods  
Between the dates of January 2005-September 
2009, the files of 55 adults, who had been 
diagnosed with MDS according to WHO 
classification by the Department of Adult 
Hematology of the Faculty of Medicine of 
Ondokuz Mayıs University, were 
retrospectively examined. Complete blood 
count, biochemical analysis, peripheral spread, 
bone marrow aspiration, bone marrow biopsy 
examinations, cytogenetic and fluorescence in 
situ hybridization (FISH) analyses were made 
for all cases. The patients’ hometown, age, 
cytopenia rate at the moment of diagnosis, 
organomegaly, bone marrow blast percentage, 
cytogenetic and FISH analysis results, bone 
marrow biopsy results and IPSS score were 
recorded. The patients’ cytogenetic and FISH 
analyses were studied by the Department of 
Child Genetics of Ondokuz Mayıs University. 
The obtained data was analyzed with statistics 
software of SPSS 15 (Statistical Package 
Social Science) for Windows. The statistical 
analyses were made with the chi-square test. 
The statistical significant limit was accepted as 
p<0.05 value. 
 
Results 
The total of 55 patients, 23 (41.8%) of whom 
are women and 32 (58.2%) men, were taken 
into evaluation. The average age of the patients 
were found to be 69 (43-82). There was not a 
significant relationship between the age and 
gender of the patients (p>0.05). 54% of the 
patients applied from Samsun, 21% from 
Ordu, and the rest of them applied from Rize, 
Artvin and Giresun as 25% of them applied 
from the provinces of Sinop and Amasya, 
mostly.  
At the moment of application, Hemoglobin 
(Hb) was under 10 gr/dl in 54 (98.2%) cases, 
neutropenia was existing (the number of 
neutrophil under 1500/mm3) in 28 (50.9%) 
cases, thrombocytopenia (the number of 
thrombocyte was under 100 thousand/mm3) in 
35 (63.6%) cases, and pancytopenia in 24 
(43.6%) cases When the performed 
examination and scans were examined, only 
hepatomegaly was found in 8 (14.5%) cases, 
only splenomegaly in 4 (7.3%) cases and 
hepatosplenomegaly in 5 (9.1%) cases. The 
number of cases without hepatosplenomegaly 
was 38 (69.1%). 
When our patients, diagnosed with MDS, were 
classified according to the WHO criteria, 13 
(23.6%) cases were diagnosed as RA-RARS, 
29 (52.7%) as RCMD-RS, 5 (9.1%) as RAEB-
1, 4 (7.3%) as RAEB-2, 3 as (5.5%) as MDS 
5q, and 1 (1.8%) as Secondary MDS. During 
making diagnoses for the patients, ring 
sideroblast percentages could not be counted 
because bone marrow was not painted with 
iron dye in our hematology laboratory. Our RA 
and RARS cases were examined under RA, 
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together. The same was true for RCMD and 
RCMD-RS diagnoses. 
When the patients’ diagnoses and 
organomegaly frequency are compared, a 
significant relationship between them could 
not be found (p>0.05). 
In the evaluation of our patients’ bone marrow 
biopsies, the bone marrow symptoms were 
found in 31 (56.4%) cases, normocellular in 9 
(16.4%) cases, hypercellular in 9 (16.4%) 
cases, insufficient in 3 (5.5%) and leukemic 
infiltration in 3 (5.5%) cases. 2 of 3 patients, 
who were concluded as leukemic infiltration, 
had RAEB-1, and the remaining 1 case had the 
diagnosis of RAEB-2. 
When the cytogenetic results of the patients 
were examined, a significant relationship 
could not be found between the cytogenetic 
results, age and gender (p>0.05). When the 
cytogenetic examination of the patients was 
evaluated, cytogenetic anomaly was found in 
29 (52.7%) cases. Isolated 5q deletion was 
found in 5 (9.1%) of our cases. Trisomy was 
found in 4 (7.2%) of our cases in total as 
isolated in 2 cases and together with complex 
chromosomal anomalies in 2 cases. 
Monosomy 7 was found at the rate of 3.6%. 
Isolated monosomy 7 was not found. 
When the patients’ cytogenetic results and 
cytopenia rates were compared, a significant 
relationship could not be found. The patients, 
who had complex chromosomal anomalies, 
mostly applied with pancytopenia. 
When the chromosome anomalies of our 
patients were taken into consideration 
according to the WHO classification, it was 
observed that the cytogenetical anomaly 
frequency was more often in the cases, 
diagnosed with RCMD-RS. The existence of 
complex cytogenetical anomalies could not be 
associated according to the MDS subgroup. 
Being only a diagnoses criteria, del 5q 
anomaly was displayed in MDS 5q in an 
isolated manner. Again similarly, del 7q was 
found in our Secondary MDS case. The 
primary diagnosis of our Secondary MDS 
patient was Non Hodgkin Lymphoma, and 
transformed into MDS after chemotherapy. As 
we stated it before, del 7q was seen in 
Secondary cases at high rates. 
When the IPSS scores of the patients were 
compared with their current diagnoses, a 
significant relation could not be found 
(p>0.05). 
When the IPSS scores of the patients were 
compared with mortality, a significant relation 
was found (p<0.05). While there was not any 
mortality in all of the patients in the low risk 
group, there were mortalities in 6 (23%) cases 
in Medium-1 risk group, 3 (60%) in Medium-
2 group, in 1 (100%) in High risk group. 
Because the cytogenetic result of our 3 cases 
were not known, their IPSS score could not be 
determined. In comparison to our total number 
of patients, the mortality rate was determined 
as 23.6% with 13 cases. 
The total of 8 cases under monitoring turned 
into AML, 3 of them were Mid-1 when their 
IPSS scores are considered, whereas the IPSS 
scores could not considered for the remaining 
4 patients, 1 of whom was determined to be in 
the high risk group, as their cytogenetic result 
could not be obtained. There was no significant 
relationship between MDS subgroups and 
AML and no significant relationship was found 
in our RA-RARS cases. Our 3 cases, diagnosed 
with RCMD-RS, 2 cases, diagnosed with 
RAEB-1, and 3 cases, diagnosed with RAEB-
2, transformed into AML. Here, 75% of our 
RAEB-2 patients, constituting high blast 
number, transformed into AML (p>0.05). 
Within this period that we took into 
examination, 6 of our 13 cases died by 
transforming into AML, and the remaining 7 
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patients died out of infection. The average life 
expectancy of deceased patients were found to 
be 6 (1-17) months since the date of diagnosis. 
While 8 cases were above the age of 70, 5 of 
our cases were under 70. 
When the mortalities of the patients are 
compared according to the MDS subgroups, a 
significant relationship could not be found. 2 
of our 5 cases, who was diagnosed with 
RAEB-1 and died, transformed to AML, and 
the remaining 3 cases died out of infection. 
 
Discussion 
In our study, 41.8% of 55 patients were 
women, and 58.2% men. In literature and the 
conducted studies, the MDS incidence in male 
patients was seen to be a little more in 
comparison to women, in general. In our study, 
the ratio of men/women was 1.3. The youngest 
of our patients was at the age of 43 and the 
oldest one was 81. The average age was found 
to be 69. In the sources, when MDS 
epidemiology is examined it is seen that the 
average age is 68 and it was seen frequently in 
these decades [4]. In a 10-years-long 
retrospective study that was made by Maura et 
al. [7], 40 patients were evaluated and the ratio 
of men/women was found to be 0.6/1. Again in 
this study, the average age was found to be 
64.1. In another study that was made by Sendi 
et al. [8], 117 MDS patients were examined, 
and the average age was found to be 58 and the 
ratio of men/women to be 1.7. In an 18-years-
long study that was made by Li et al. [9], 351 
MDS patients were examined, and the average 
age was found to be 45 and the ratio of 
men/women to be 2/1. A relationship for the 
organomegalies, which were determined with 
the physical examination and scanning 
methods, of our patients, diagnosed with MDS, 
could not be found with MDS subgroups. In 
our study, while the rate of isolated 
splenomegaly was 7.3%, if we count our 
patients with hepatosplenomegaly this ratio 
increases to 16.4%. In a study which Steensma 
et al. [10] made, 218 patients were taken into 
evaluation, and the splenomegaly rate was 
found to be 16%. In bone marrow examination, 
normocellular was found in 31 cases, 
hypercellular in 9 cases, hypocellular in 9 
cases, and leukemic infiltration in 3 cases, and 
it was found to be insufficient in 3 cases. If it 
is evaluated regarding the total, normal or 
hypercellular bone marrow was found in 40 
cases, and a hypocellular bone marrow was 
determined in 16.4% of the cases. In literature, 
the hypocellularity is around 20% in MDS 
patients [4]. This rate is suitable with the value 
of 20% given in the literature. 
When we examined the MDS subgroups; in the 
comparison of the WHO data [4] and our 
patient population, the RAEB-1 and RAEB-2 
incidence was found to be 9% in our data while 
it was 40% in the WHO data. The existence of 
a significant difference in comparison to other 
subgroups can be related to the low number of 
our cases. As a reason of this difference, it is 
thought that RAEB cases with high risk of 
leukemia may be transformed into leukemia 
until the time of diagnosis due to 
socioeconomic reasons. While the RAEB 1-2 
rates were close to the WHO rates in the study, 
made by Romeo et al. [7] the RCMD-RS rate 
was lower than our study and the WHO data. 
When the cytogenetic anomalies of our 
patients were studied, an anomaly was 
determined in 52.7% of the cases. When we 
look at the literature, the cytogenetic anomaly 
incidence changes between 30 and 50% in the 
studies that were made on the MDS patients 
[8,11,12]. In the study, which was made by 
Romeo et al. [7] with 40 people, the 
cytogenetic anomaly was determined to be at 
35%, in the one, which was made by Sendi et 
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al. [8] with 117 people, at 55%, and in the one, 
which was made by Li et al. [9] with 351 
people, at 67.5%.  
When the relationship between the cytogenetic 
analysis results and gender, a significant 
relationship could not be found. When the 
chromosome anomalies of our patients were 
taken into consideration according to the WHO 
classification, it was observed that the 
cytogenetical anomaly frequency was more 
often in the cases, diagnosed with RCMD-RS. 
The existence of complex cytogenetical 
anomalies could not be associated according to 
the MDS subgroup. Being only a diagnosis 
criterion, del (5q) anomaly was shown in MDS 
5q as isolated. Again similarly, del 7q was 
found in our Secondary MDS case. The 
primary diagnosis of our Secondary MDS 
patient was Non Hodgkin Lymphoma, and 
transformed into MDS after chemotherapy. As 
we stated it before, del 7q was seen in 
Secondary cases at high rates. In the MDS 
cases, del 5(q), monosomy 7, trisomy 8, del 8, 
20q-, -Y and del (7q) anomalies are observed. 
By this reason, the anomalies that belong to 
chromosome 5 and 7 can be interpreted as the 
AML transformed by MDS in the AML cases. 
There are not any cytogenetic anomaly unique 
for the subtype of the cases [11,12]. In our 
population, the anomalies belonging to the 5th, 
7th and 8th chromosomes were observed more 
frequently. In the study, made by Mauro et al., 
the chromosome 5q anomaly was found to be 
at the rate of 20%, monosomy 7 to be 15% and 
trisomy 8 to be 5%. In the study, made by 
Halima et al., the chromosome 5q anomaly was 
found to be at the rate of 14%, monosomy 7 to 
be 7% and trisomy 8 to be 4% [7,8]. 
Again in our study, while 2 of the 8 cases, 
which subsequently transformed into AML, 
were found to have a normal cytogenetic 
structure, 1 of them to have a -Y and t (3-21) 
anomaly, 1 of them to have Del5q and t (1.7) 
anomaly, the remaining 4 cases’ cytogenetic 
examination could not be determined due to 
insufficient metaphase. Because the number of 
cases is scarce and the cytogenetic 
examination of 4 cases could not be 
determined, a prognostic cytogenetic anomaly 
could not be found in terms of transformation 
to AML. While calculating the IPSS score in 
MDS, the blast percentage in the bone marrow, 
the cytopenia rate and chromosomal anomaly 
values must be known. The obtained scores are 
classified as low, medium and high risk groups. 
When the MDS subgroups were compared 
with the IPSS scores, a significant relation 
could be found. 
In terms of mortality, RAEB 1-2 has a higher 
risk among the subgroups in comparison to 
RCMD-RS and RA-RARS groups. In our 
story, the IPSS scores were concentrated in the 
low risk group for RA-RAS, in the medium 
risk group for RCMD-RS and in the medium-
high risk group for RAEB-1-2. When the MDS 
subgroups were compared with the IPSS 
scores, a significant relation could be found. In 
our RA-RARS cases, no transformation ALM 
was seen in 4 years of monitoring. Our 3 cases, 
diagnosed with RCMD-RS, 2 cases, diagnosed 
with RAEB-1, and 3 cases, diagnosed with 
RAEB-2, transformed into AML. Here, 75% of 
our RAEB-2 patients, constituting high blast 
number, transformed into AML. When we 
compared to the literature, along with the fact 
that our findings are similar, that the 
percentage increased to 75 percent in RAEB-2 
cases can be explained with the low number of 
cases. In the study, which was made by Breccia 
et al. [8], the transformation rates to AML was 
found to be 27% for RAEB-1 and 44% for 
RAEB-2. In the study, which was made by 
Kazuma et al. [8], while the transformation of 
RAEB-1 to AML was 37.5% the 
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transformation rate of RAEB-2 to AML was 
found to be 50%.  When the mortalities of the 
patients are compared according to the MDS 
subgroups, a significant relationship could not 
be found. However, when we examine RAEB 
1 and 2 under a single subject by removing 
Secondary MDS and MDS 5q diagnoses from 
MDS subgroups because of the low number of 
cases, a significant relationship was 
determined between mortality and MDS 
subgroups. In terms of its relationship with 
mortality, the higher the blast rate got in bone 
marrow (as the diagnosis revised from RA-
RARS to RAEB-2), the higher mortality 
became. According to the Literature, mortality 
is in the order of RAEB-1-2, RCMD, RARS, 
RA in order [4]. In the study, in which Breica 
et al. [14], compared RAEB-1 and RAEB-2, 
RAEB-1’s mortality was found to be 44% 
while RAEB-2’s mortality was found to be 
67%. The relationship between mortality and 
IPSS score was found to be insignificant in our 
study. Because the cytogenetic result was not 
certain, the IPSS score could not be determined 
in some cases, and it could be because of the 
low number of cases. Along with this, such a 
relationship cannot be established due to the 
different responds that the patients given to 
treatments. 
As the result, the age average and gender ratio 
of the patients were found to be proportional to 
other studies in MDS. When the MDS 
subgroups are examined, their occurrence 
frequencies are similar to the literature. In our 
patients, the percentage of the chromosomal 
anomalies, which are seen the most frequently 
in MDS, is in compliance with other studies. 
Although it is presented in other studies that 
the existence of complex cytogenetic 
anomalies increases mortality, the fact that 12 
patients’ cytogenetic results were insufficient 
in our study caused not being able to show this 
relationship. The patients’ transformation to 
AML was associated with their diagnoses. This 
relationship is in correlation with other studies. 
Mortality is related to the ratio of blasts in bone 
marrow and the rate of cytopenias that 
developed in connection. It can be suggested 
that the age factor can also be included into the 
score system in determining the prognosis with 
IPSS. Whatever the blast percentage is in bone 
marrow, the age of the patients is factor in 
effecting the prognosis, including cytogenetic 
anomaly. Age is an important factor in 
selection of the treatment to be chosen. 
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